


LA JOLLA CANCER RESEARCH FOUNDATION
ANIMAL USAGE FORM



AUF 1413

1. PRINCIPAL INVESTIGATOR OFFICE PHONE HOME/EMERGENCY PHONE
 WAYNE A. BORDER, M.D. 226 (714) 770-4602

2. OTHER INVESTIGATOR OFFICE PHONE HOME/EMERGENCY PHONE
 LUCIA LANGUINO, PH.D. 230 539-0609

3. SENIOR TECHNICIAN OFFICE PHONE HOME/EMERGENCY PHONE

4. PROJECT TITLE
 ANTI-HUMAN TGF β CYCLIZED PEPTIDE

5. GRANT NUMBER, IF ANY NEW RENEWAL PILOT PROJECT NUMBER
 250200 X

6. START DATE END DATE QUANTITY: MICE RATS RABBITS GPI OTHER (SPECIFY)
 2

7. PROJECT GOAL (SEE INSTRUCTIONS)
 To produce quantities of anti-human TGF β cyclized peptide for use in kidney disease research.

8. RATIONALE (SEE INSTRUCTIONS)
 Rabbits produce high quality antiserum which can be used for identification of human TGF β in tissue samples and in vitro assays to study progression of kidney injury.

9. DESCRIBE USE OF ANIMALS (SEE INSTRUCTIONS)
 All injections/bleedings to be performed by animal care facility personnel.
 1. Pre-bleeding 20 ml from ear vein.
 2. Inject 500 μ g TGF β cyclized purified peptide (0.5 ml antigen in PBS + 0.5 ml FCA) subcutaneously in 2 sites.
 3. After one month, boost with 125 μ g antigen (0.25 ml antigen in PBS + 0.25 ml incomplete adjuvant) subcutaneously, 2 sites.
 4. After 10 days, bleed 50 ml from alternating ear veins 3 times.
 5. Repeat steps 3-4 at 4-6 week intervals.

10. PAIN LEVEL A B C (IF B OR C READ INSTRUCTIONS. PROVIDE DESCRIPTION OR JUSTIFICATION HERE)

CONFIDENTIAL

11. EUTHANASIA (SEE INSTRUCTIONS)

DURING PROJECT	METHOD OR TECHNIQUE	CO.	CERV. DISLOC.	RETAIN CARCASSES?
END OF PROJECT		O.D.	OTHER (SPECIFY)	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>

12. SIGNATURES

PI <u>WABorde</u>	DATE	U2 05334	DATE
APF	DATE		

ANIMAL PROCEDURE REQUEST

(For procedures to be performed by Animal Facility personnel)
Return this form to the Animal Facility Office.

LJCRF

TODAY'S DATE: _____

Principal Investigator E. ROSLAHT

LUCIA R. LARGUINHO
Investigator/Technician

Phone

230

Lab No.

Phone

Lab No.

This procedure relates to the project outlined on Animal Usage Form No. _____

Date or Dates on which this procedure is required (please allow 7 days for scheduling):


- 1 12/13/88 50 ml (If more than 8 procedures are required, attach a second form)
- 2 12/16/88 "
- 3 12/21/88 Estm 100 ml
- 4 _____
- 5 _____
- 6 _____
- 7 _____
- 8 _____

Describe the procedure(s) required:

Vol. of blood to be collected each procedure:

ml.

Injection 6 tablets 2 PC
2 TGF 2 Linc. Appl.
2 " 2 cyclic





Injection of 2 rabbits with Linear 78-103 peptide
no 86-87 from TGF β .

2 " with lyophilized 78-103 " .
no 88-89

Procedure: 2 mg / rabbit of each peptide.

- 2 mg peptide were dissolved in 250 μ l DAW
- 0.5 mg Methylated BSA were ~~added to the solution to couple the peptide~~
~~added to the solution to couple the peptide~~
(Sigma A1009 : M₂BSA)
- vortex 30''
- Added 250 μ l Freund's adjuvant complete
- mixed 1h with homogenizer.
- 0.5 ml solution was injected in each rabbit

Note : Both peptides were difficult to dissolve.
" " were not HPLC purified



Injection of 2 rabbits. Linear TGF β peptide

Cyclic

PG peptide

Procedure

except Freund's incomplete adjuvant was used

For notes:

KLH-peptide was already coupled

I only mixed to F.i. 20% ; mix 1h 4°C

inject 0.5ml

Rabbit

n° 1284
1285

for PG

ALF 1385